Denali Therapeutics Inc - Asset Resilience Ratio

Latest as of March 2026: 47.40%

Denali Therapeutics Inc (DNLI) has an Asset Resilience Ratio of 47.40% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

$600.06 Million

Cash + Short-term Investments

Total Assets

$1.27 Billion

All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Denali Therapeutics Inc's Asset Resilience Ratio has changed over time. Check strategic asset allocation of Denali Therapeutics Inc to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Denali Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Denali Therapeutics Inc (DNLI) total market value.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$600.06 Million	47.4%
Total Liquid Assets	$600.06 Million	47.40%

Asset Resilience Insights

Very High Liquidity: Denali Therapeutics Inc maintains exceptional liquid asset reserves at 47.40% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Denali Therapeutics Inc Industry Peers by Asset Resilience Ratio

Compare Denali Therapeutics Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	10.93%
Royalty Pharma Plc NASDAQ:RPRX	Biotechnology	0.11%
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Shanghai Allist Pharmaceuticals Co. Ltd. A SHG:688578	Biotechnology	21.11%
Apogee Therapeutics, Inc. Common Stock NASDAQ:APGE	Biotechnology	47.01%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Beijing Hotgen Biotech Co Ltd SHG:688068	Biotechnology	20.87%

Annual Asset Resilience Ratio for Denali Therapeutics Inc (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Denali Therapeutics Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	57.87%	$662.55 Million	$1.14 Billion	+10.03pp
2024-12-31	47.84%	$657.37 Million	$1.37 Billion	-30.80pp
2023-12-31	78.64%	$907.40 Million	$1.15 Billion	+2.06pp
2022-12-31	76.57%	$1.12 Billion	$1.46 Billion	+35.84pp
2021-12-31	40.73%	$571.93 Million	$1.40 Billion	-19.27pp
2020-12-31	60.00%	$962.55 Million	$1.60 Billion	-0.72pp
2019-12-31	60.72%	$335.91 Million	$553.23 Million	+2.23pp
2018-12-31	58.49%	$387.17 Million	$661.98 Million	+19.89pp
2017-12-31	38.60%	$187.85 Million	$486.72 Million	-12.49pp
2016-12-31	51.09%	$138.48 Million	$271.07 Million	--

pp = percentage points

About Denali Therapeutics Inc

NASDAQ:DNLI USA Biotechnology

Market Cap

$3.65 Billion

Market Cap Rank

#4578 Global

#1568 in USA

Share Price

$23.02

Change (1 day)

-5.46%

52-Week Range

$12.75 - $27.21

All Time High

$93.56